Results 171 to 180 of about 7,834 (208)

Talazoparib Bests Chemo for Breast Cancer

Cancer Discovery, 2018
Abstract Patients with advanced or metastatic HER2-negative breast cancer and germline BRCA1/2 mutations may benefit from talazoparib, according to data from a phase III trial. Compared with chemotherapy, the investigational PARP inhibitor induced some complete responses, prolonged progression-free survival, and improved patients ...
openaire   +2 more sources

Proteomic analysis of talazoparib resistance in triple‐negative breast cancer cells

Journal of Biochemical and Molecular Toxicology, 2020
AbstractTalazoparib (TAL) has been effectively used for the treatment of gBRCA1/2‐mutated HER2‐negative metastatic breast cancer. However, acquired resistance to TAL remains a major challenge that impedes the clinical success of TAL treatment. Therefore, elucidation of proteins and pathways that contribute to or are affected by the TAL resistance is ...
Gamze Guney Eskiler, Sevinc Yanar, Gurler Akpinar, Murat Kasap   +3 more
openaire   +3 more sources

Abstract 3100: Nanoformulated Talazoparib and Olaparib for enhanced delivery

Cancer Research, 2017
Abstract Introduction: PARP inhibitors such as Talazoparib and Olaparib exploit deficiencies in DNA repair pathways, making them attractive candidates for treatment of a number of different cancers. These drugs are particularly effective when used in combination with other DNA damaging agents such as chemotherapeutics and radiation ...
Paige Baldwin, Rajiv Kumar, Edward Favours, Karen Liby, Raushan Kurmasheva, David Kozono, Srinivas Sridhar   +6 more
openaire   +1 more source

Talazoparib for the Treatment of Metastatic Castration-resistant Prostate Cancer

American Journal of Clinical Oncology
Breast and prostate cancer are among the most commonly diagnosed cancers worldwide. Recent advances in tumor sequencing and gene studies have led to a paradigm shift from treatment centered on the type of tumor to therapy more focused on specific immune phenotype markers and molecular alterations.
Zaheer Qureshi, Eeshal Fatima, Adnan Safi, Mikail Khanzada, Faryal Altaf   +4 more
openaire   +2 more sources

Doxorubicin/niraparib/talazoparib

Reactions Weekly, 2021
openaire   +1 more source

Talazoparib: a new biomarker-directed therapy in advanced prostate cancer

The Lancet Oncology, 2021
Vincenza, Conteduca, Ugo, De Giorgi
openaire   +2 more sources

Synthesis of Talazoparib

Synfacts, 2016
openaire   +1 more source

Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial

Lancet, The, 2023
Joan Carles
exaly  

Talazoparib plus temozolomide appears efficacious in ES-SCLC

Medicom Conference Report WCLC 2022, 2022
Jonathan Goldman, Robert van den Heuvel
openaire   +1 more source

The non-canonical target PARP16 contributes to polypharmacology of the PARP inhibitor talazoparib and its synergy with WEE1 inhibitors

Cell Chemical Biology, 2022
Vinayak Palve, Daniel S Bejan, Alvaro N A Monteiro   +2 more
exaly